In vivo quantification of neurofibrillary tangles with [18F]MK-6240

• Published in: Alzheimer's research & therapy Vol. 10; no. 1; pp. 74 - 14
• Main Authors: Pascoal, Tharick A., Shin, Monica, Kang, Min Su, Chamoun, Mira, Chartrand, Daniel, Mathotaarachchi, Sulantha, Bennacef, Idriss, Therriault, Joseph, Ng, Kok Pin, Hopewell, Robert, Bouhachi, Reda, Hsiao, Hung-Hsin, Benedet, Andrea L., Soucy, Jean-Paul, Massarweh, Gassan, Gauthier, Serge, Rosa-Neto, Pedro
• Format: Journal Article
• Language: English
• Published: London BioMed Central 31.07.2018; BioMed Central Ltd; BMC
• Subjects: Alzheimer's disease; Analysis; Biomedical and Life Sciences; Biomedicine; Brain research; Clinical trials; Cognitive ability; Dementia; Equilibrium; Geriatric Psychiatry; Geriatrics/Gerontology; Kinetics; Medical imaging; Neurofibrillary tangles; Neurology; Neurosciences; PET imaging; Ratios; Tau positron emission tomography; Tau positron emission tomography; Alzheimer’s disease; Neurofibrillary tangles
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-018-0402-y

Background Imaging agents capable of quantifying the brain’s tau aggregates will allow a more precise staging of Alzheimer’s disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau imaging agent [ 18 F]MK-6240. Methods In vitro properties of [ 18 F]MK-6240 were estimated with autoradiography in postmortem brain tissues of 14 subjects (seven AD patients and seven age-matched controls). In vivo quantification of [ 18 F]MK-6240 binding was performed in 16 subjects (four AD patients, three mild cognitive impairment patients, six healthy elderly individuals, and three healthy young individuals) who underwent 180-min dynamic scans; six subjects had arterial sampling for metabolite correction. Simplified approaches for [ 18 F]MK-6240 quantification were validated using full kinetic modeling with metabolite-corrected arterial input function. All participants also underwent amyloid-PET and structural magnetic resonance imaging. Results In vitro [ 18 F]MK-6240 uptake was higher in AD patients than in age-matched controls in brain regions expected to contain tangles such as the hippocampus, whereas no difference was found in the cerebellar gray matter. In vivo, [ 18 F]MK-6240 displayed favorable kinetics with rapid brain delivery and washout. The cerebellar gray matter had low binding across individuals, showing potential for use as a reference region. A reversible two-tissue compartment model well described the time–activity curves across individuals and brain regions. Distribution volume ratios using the plasma input and standardized uptake value ratios (SUVRs) calculated after the binding approached equilibrium (90 min) were correlated and higher in mild cognitive impairment or AD dementia patients than in controls. Reliability analysis revealed robust SUVRs calculated from 90 to 110 min, while earlier time points provided inaccurate estimates. Conclusions This evaluation shows an [ 18 F]MK-6240 distribution in concordance with postmortem studies and that simplified quantitative approaches such as the SUVR offer valid estimates of neurofibrillary tangle load 90 min post injection. [ 18 F]MK-6240 is a promising tau tracer with the potential to be applied in the disease diagnosis and assessment of therapeutic interventions.